^
Association details:
| Biomarker: | WEE1 mutation + PKMYT1 overexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
Published date:
04/16/2021
Excerpt:
A 3 + 3 dose escalation design was used, with adavosertib given once daily on days 1-5 and 8-12 in 21-day cycles....One patient who progressed rapidly had a tumor WEE1 mutation and potentially compensatory PKMYT1 overexpression.
DOI:
10.1158/1078-0432.CCR-21-0329
